drugset / Trial / NCT06020118

Summary

This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.

Timeline

Start
2023-09-25
Primary completion
2024-03-07
Completion
2024-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject BNT162b2 Messenger RNA (mRNA)
Subject Flucelvax Vaccine

Indications